Daily FNArena News - Australia

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

Opportunity In Aristocrat Leisure’s Pullback

Jul 30 2026

The Chartist sees a healthy pause in Aristocrat Leisure shares, following the breakout, setting the stage for another leg higher


AI Infrastructure: From Capex To Productivity

Jul 30 2026

Despite growing investor scepticism, analysts believe the next phase of the AI investment cycle will be driven by productivity gains, data centre expansion and a widening group of ASX-listed beneficiaries


James Hardie’s Q1 Leaves Questions Unanswered

Jul 28 2026

A stronger-than-expected first-quarter update has prompted brokers to lift earnings forecasts and price targets for James Hardie Industries


The Market In Numbers – 25 Jul 2026

Jul 25 2026

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements


Strong Result, Can Telix Continue To Deliver?

Jul 22 2026

Telix has continued to outperform operationally in 2026, but future upside is increasingly dependent on pipeline execution, regulatory approvals and therapeutic progress.


AI’s Show Me The Money Moment

Jul 22 2026

AI monetisation is becoming measurable as Australian banks, businesses and data centre investment accelerate adoption, supporting productivity gains while reshaping the economy and labour market


The Market In Numbers – 18 Jul 2026

Jul 18 2026

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements


Supermarkets Behemoths Remain In Focus

Jul 15 2026

Supplier surveys and consumer spending data have analysts divided over supermarket valuations and where the best value lays across the consumer sector


Are Headwinds Building For ResMed In FY27?

Jul 14 2026

While one broker has turned more cautious on ResMed due to a one-off cost and risk of rising competition, analysts broadly welcome the MatrixCare sale as a strategic refocus backed by a sizeable shareholder return


The Market In Numbers – 11 Jul 2026

Jul 11 2026

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements



Analyse The Market From A Different Angle